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ABSTRACT
Previously, we have demonstrated that 17α-ethynylestradiol (EE) induces rat 
multidrug-resistance associated protein 3 (Mrp3, Abcc3) expression 
transcriptionally through estrogen receptor-α (ER-α) activation. We explored the 
effect of EE on MRP3 expression of human origin. HepG2 cells were 
transfected with ER-α and incubated with EE (1-10-50 µM) for 48 h. MRP3 
protein and mRNA levels were measured by Western blotting and Real time 
PCR, respectively. EE up-regulated MRP3 protein and mRNA at 50 µM only in 
ER-α(+)-HepG2 cells. The in silico analysis of mrp3 promoter region 
demonstrated absence of estrogen response elements, but showed several Ap-
1 binding sites. We further evaluated the potential involvement of the 
transcription factors c-JUN and c-FOS (members of Ap-1) in MRP3 up-
regulation. ER-α(+) HepG2 cells were incubated with EE and c-FOS and c-JUN 
levels measured by Western blotting in nuclear extracts. EE up-regulated only 
c-JUN. Experiments of overexpression and knock-down of c-JUN by siRNA 
further demonstrated that this transcription factor is indeed implicated in MRP3 
upregulation by EE. Co-immunoprecipitation assay demonstrated that EE 
induces c-JUN/ER-α interaction, and chromatin immunoprecipitation assay 
showed that this complex is recruited to the AP-1 binding consensus element 
present at the position (-1300/-1078bp) of human mrp3 promoter. We conclude 
that EE induces MRP3 expression through ER-α, with recruitment of ER-α in 
complex with c-JUN to the human mrp3 promoter.
Key words: drug transporter, AP-1, estrogen, multidrug resistance, nuclear 
receptor, c-JUN.
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1. INTRODUCTION.
Multidrug resistance-associated protein 3 (MRP3/ABCC3) is a member 
of the superfamily of adenosine tri-phosphate (ATP)-binding cassette (ABC) 
transporters. It is expressed in several epithelial cells including hepatocytes (1). 
Due to its basolateral localization it transports into blood a wide range of 
endogenous and exogenous compounds such as sulphated bile salts, bilirubin 
glucuronides, specific anti-cancer drugs such as methotrexate, etoposide,
teniposide, etc (2-6). Under physiological conditions its expression is low, but it 
is highly inducible by drugs such as acetaminophen (7) and phenobarbital (8),
or under several cholestatic situations such as later stages of primary biliary 
cirrhosis and extrahepatic cholestasis of different etiology (9). Induction of
MRP3 activity results in re-directioning the secretion of common MRP 
substrates from the apical to the basolateral pole.
It is known that estrogens are involved in the pathogenesis of both oral 
contraceptive-induced cholestasis and cholestasis of pregnancy (10, 11). In 
previous work we demonstrated that 17α-ethynylestradiol (EE), a synthetic 
estrogen widely used in contraceptive formulations and in estrogen replacement 
therapies, up-regulates hepatic Mrp3 in rats (12, 13). We later demonstrated 
that induction of Mrp3 by EE in rat liver is independent of cholestasis and 
occurs via activation of ER (14), though the underlying mechanism down-
stream ER remains unknown. The canonical model for ER-mediated regulation 
of gene expression involves the direct binding of dimeric ER to DNA sequences 
known as estrogen response elements (ERE), which are specific, inverted 
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palindromic sequences. In addition, ER can indirectly associate with promoters 
through protein-protein interactions with other DNA-binding transcription factors 
such as specificity protein 1 (Sp1) or activator protein-1 (AP-1), a complex 
composed of c-JUN protein homodimers or c-JUN/c-FOS heterodimers. In 
either case, interaction of ERs with estrogens leads to transcriptional activation 
of the associated genes via recruitment of co-activators and components of the 
basal transcriptional machinery (15). The liver expresses predominantly ER-α 
(16) and its expression is under multihormonal regulation.
Until present there are no reports about the effect of estrogens on human 
MRP3 expression. As interactions of nuclear receptors with selective ligands 
may vary between species and considering the differences between rat and 
human mrp3 promoters (17, 18), we explored whether EE is also able to induce 
MRP3 in HepG2 cells, a human hepatoma cell line, and whether ER-α is 
involved. Additionally, we explored in these cells the intervention of potential 
candidates that can mediate the response downstream ER-α, such as the 
transcription factor AP-1.
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2. MATERIALS AND METHODS.
2.1. Chemicals.
EE, leupeptin, phenylmethylsulfonyl fluoride, pepstatin A, were obtained 
from Sigma Aldrich Chemical Company (St. Louis, MO). All other chemicals 
were of analytical grade purity, and used as supplied.
2.2. Cell culture and treatment with EE.
HepG2 cells were grown in monolayer culture and maintained in F-12 
(Invitrogen, Carlsbad, CA, USA) and phenol-red DMEM (1:1) supplemented 
with 10% FBS (PAA, Pasching, Austria) (v/v) in a humidified atmosphere of 5% 
CO2 and 37ºC. Three days prior to harvesting, 3.5 x 10
5 cells were seeded into 
six-well plates and 24 h later, the medium was changed to phenol red-free 
DMEM/F-12 supplemented with 10% charcoal-dextran treated FBS (Hyclone 
Laboratories, Logan, UT), and treated with EE at 1, 10 or 50 µM for 48 h.
2.3. Transfection and treatment with EE.
The expression vector encoding human ER-α (pCMV5-hERα) and the 
estrogen-responsive reporter plasmid 4XERE-TK-Luc, which contains four 
copies of ERE in front of a thymidine kinase promoter reporter construct, were 
a gift from Dr. Benita Katzenellenbogen (University of Illinois, Urbana-
Champaign, IL). The expression vectors encoding c-JUN and the empty vector
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were a gift from Dr. Beatriz Caputto (Universidad Nacional de Córdoba, 
Córdoba, Argentina). Plasmid DNA was purified by using EndoFree Plasmid 
Maxi kit from Qiagen Sciences (Maryland, USA). HepG2 cells were grown as 
described above. A day before transfection, 3.5 x 105 cells were subcultured 
into 6 well-plates in phenol red-free DMEM/F12 supplemented with 10% 
charcoal stripped FBS and glutamine. Transfections were performed by using 
Lipofectamine2000 (Invitrogen, Carlsbad, CA) following manufacturer’s 
instructions. Cells were transfected with 5 µg of pCMV5-hERα or pCMV5 
(empty vector) as a negative control. In transcription factor over-expression 
experiments, cells were transfected with 4 µg of pCMV5-hERα and 1 µg of c-
JUN plasmids or with their respective empty vectors. To monitor the estrogen-
induced transcriptional activation, cells were subcultured into a 10 cm plate, 
and 24 h later, transfected with 5 µg of the estrogen-responsive reporter 
plasmid 4X ERE-TK-Luc, and 5 µg of pCMV5-hERα or 5 µg of empty vector 
pCMV5 as a negative control. Eighteen h after transfection, the media were 
removed and the cells washed twice with PBS and re-plated in a 96-well plate. 
The cells were treated with vehicle (dimethyl sulfoxide) or estrogens (EE at 1, 
10 or 50 µM or 17β-estradiol at 1, 10 or 100 nM). The final concentration of 
dimethyl sulfoxide was adjusted to 0.08% (v/v). After 48 h, cells were washed 
with PBS and luciferase activity measured using Luciferase Assay System 
following the manufacturer’s protocol (Promega, Madison, WI). For Western 
blot or real time PCR studies, the media were removed 18 h after transfection, 
the cells washed twice with PBS, and replaced with fresh media containing EE 
(1, 10 or 50 µM). After 48 h of incubation, cells were washed with PBS and 
harvested for preparation of whole-cell extract or total RNA extraction.
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2.4. Western blot studies.
HepG2 cells were harvested and lysed in RIPA buffer (Pierce, Rockford, 
IL), 0.1 µM phenylmethylsulfonyl fluoride and 35 nM leupeptin. Nuclear extracts 
were prepared for detection of c-JUN and c-FOS. Briefly, HepG2 cells were 
harvested in sucrose 0.3 M, 0.1 µM phenylmethylsulfonyl fluoride and 35 nM 
leupeptin (Sigma Aldrich Chemical Company, St. Louis, MO), and samples 
sonicated and centrifuged at 500 g for 10 min. The pellets were resuspended in 
RIPA buffer plus protease and phosphatase inhibitors and protein concentration 
measured using bovine serum albumin as standard (19). Equal amounts of cell 
protein extract were resolved on an 8% (to detect MRP3) or 12% (to detect c-
FOS and c-JUN) SDS-PAGE and transferred to nitrocellulose membranes. The 
blots were then exposed to primary antibodies: anti-MRP3 (M3II-21, Sigma, St. 
Louis, MO), anti-ER-α, anti c-JUN, anti c-FOS, anti-histone or anti-β-Actin 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA). Immunoreactive bands were 
detected using a chemiluminescence kit (ECL + Plus, Amersham Pharmacia 
Biotech, Inc., Piscataway, NJ) and quantified using the Gel-Pro Analyzer 
(Media Cybernetics, Silver Spring, MD) software.
2.5. Quantitative Real Time PCR.
Total RNA was isolated from HepG2 cells using Trizol (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol. cDNA was produced by 
using the SuperScript Preamplification System for first-strand cDNA synthesis 
Page 9 of 37
Ac
ce
pte
d M
an
us
cri
pt
9
according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Real-
time quantitative PCR was performed on cDNA samples using the MX3000P 
system (Agilent Technologies, Santa Clara CA, USA) with Platinum Taq DNA 
Polymerase (Invitrogen, Carlsbad, CA). The amount of template was quantified 
with SYBR green (Invitrogen) (20). For MRP3 mRNA amplification the forward 
primer sequence was 5´ gtccgcagaatggacttgat 3´ while the reverse primer 
sequence was 5´ tcaccacttggggatcattt 3´. Results for MRP3 were normalized to 
18S rRNA as housekeeping gene using the following primers: forward 5´
cgccgctagaggtgaaattc 3´ and reverse 5´ ttggcaaatgctttcgctc 3´. All the primers 
were used at a final concentration of 1 µM. The thermocycling regime was 95 
°C for 2 min followed by 40 cycles of 95 °C for 15 s, 55 °C for 30 s and 72 °C 
for 30 s. The amplified product size was 120 and 62 bp for mrp3 and 18S, 
respectively. PCR product sizes were confirmed by gel electrophoresis. 
Relative levels of MRP3 mRNA normalized to 18S rRNA were calculated based 
on the 2-ΔΔCt method. Specificity of the reaction was verified with a dissociation 
curve between 55°C and 95°C with continuous fluorescence measure (20).
2.6. RNA interference experiment.
HepG2 cells (5x104 cells/well) were seeded in 24 well plates, incubated 
at 37°C and subjected to transfection 24 h later. Human c-JUN was transiently 
knocked down with c-JUN siRNA (Santa Cruz Biotechnology, sc-29223), 
targeting the human transcription factor mRNA. Control siRNA-A (Santa Cruz 
Biotechnology, sc-37007), a non-targeting siRNA, was used as a negative 
control. Both groups of cells were transfected also with ER-α plasmid. 
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Transfections were performed using Dharmafect4 Transfection Reaction 
(Dharmacon, Lafayette, CO, USA) according to the manufacturer’s instructions. 
At 24 h post-transfection, the cells were exposed to EE (50 µM) for additional 
48 h, and then harvested and subject to Western blot analyses.
2.7. Co-immunoprecipitation assay.
2.5x106 HepG2 cells were plated into a 100-mm plate, transfected with 
ER-α, and treated as described in section 2.2. They were harvested 48 h after 
EE treatment. Cell lysates and immunoprecipitation were performed using 
Protein A agarose (Roche Applied Science, Germany). The antibodies used for 
immunoprecipitation were anti ER-α, c-JUN or normal rabbit IgG (H-184, SC-
45X, SC-2027, respectively, Santa Cruz Biotechnology, Inc.). Western blotting 
of immunoprecipitated ER-α and c-JUN was performed using anti ER-α or anti 
c-JUN (2Q418, SC-1694, respectively, Santa Cruz Biotechnology, Inc.).
2.8. Chromatin immunoprecipitation (ChIP) assay.
2.5x106 HepG2 cells were plated into a 100-mm plate and transfected 
with ER-α as described above. ER-α transfected HepG2 cells were treated with 
EE (50 µM, 48 h) or vehicle and cross-linked with 1% formaldehyde (37°C, 10 
min). ChIP assay was performed following manufacturer protocol (Upstate 
Biotech, NY) using rabbit antibodies to c-JUN or normal rabbit IgG as a
negative control (SC-45X, SC-2027, respectively, Santa Cruz Biotechnology, 
Inc.). An aliquot of lysates (20 µl) was taken out as input control. DNA was 
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purified by phenol/chloroform extraction and ethanol precipitation. For PCR 
analysis, we used primers that amplify 222 and 183 bp fragments of the human 
mrp3 promoter region from -1300 to -1078 and -501 to -318 bp, relative to the 
transcription start site, which include the two putative AP-1 binding sites ChIP-
1: 5´gagtccgccgtccacaccca3´ and ChIP-2: 5´cttctgtcccgttgtcgcccta3´ for AP-1 
(A) and ChIP-3: 5´tagacattttacccttcccgaa3´ and ChIP-4: 
5´cacatagggtcaagggggaac3´ for AP-1 (B) (Fig 4). The thermocycling regime
was 35 cycles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec.
2.9. Statistical Analysis.
Results are expressed as mean ± S.D. Statistical analysis was 
performed using Student t test or one-way ANOVA followed by Newman Keuls 
test. Values of p< 0.05 were considered to be statistically significant.
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3. RESULTS.
3.1. ER-α is necessary for EE to up-regulate MRP3 in HepG2 cells.
HepG2 are well differentiated cells, retain many hepatocyte-specific 
features, and represent a tool for understanding the regulation of MRP3 in a 
human liver cell line (21). We found no changes in MRP3 protein expression at 
any concentrations of EE analyzed (1, 10 or 50 µM) (Fig 1). HepG2 cells 
express ER at low levels that are insufficient for ligands to induce 
transactivation of an ERE-containing synthetic target gene under transient 
transfection conditions (22, 23). We therefore transfected HepG2 cells with a 
plasmid encoding human ER-α, and confirmed ER-α expression by Western 
blotting (data not shown). The activity of ER-α was monitored by introducing an 
estrogen-responsive indicator in which four copies of the ERE were linked to a 
thymidine kinase promoter of a luciferase expression plasmid (4XERE-TK-Luc). 
As shown in Fig 2, EE (upper panel) and 17β-estradiol (positive control, lower 
panel) treatments activated 4XERE-TK-Luc in a dose dependent manner in 
HepG2 cells transfect d with ER-α but not in those transfected with the empty 
vector. These data demonstrate that ER-α was active and able to transduce the 
estrogen signal in HepG2 cells. Western blot studies indicate that MRP3 
expression significantly increased (270%) in cells transfected with ER-α and 
incubated with 50 µM EE (Fig 3A), whereas it remained unchanged in the 
empty vector-transfected HepG2 cells at all concentrations of EE tested (Fig 
3B). Real time PCR studies showed an increase in the content of MRP3 mRNA 
in ER-α transfected HepG2 cells incubated with 50 µM EE (180%) with respect 
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to control cells, whereas no changes were observed in empty vector-
transfected cells (Fig 3C).
3.2. Changes in the expression of AP-1 are responsible for MRP3 up-
regulation by EE.
To understand how ER-α might mediate MRP3 induction by EE, we 
performed an in silico analysis using the TFSearch database 
(http://www.cbrc.jp/research/db/TFSEARCH.html). Although we could not 
identify any ERE in the mrp3 promoter sequence, the analysis located two
binding sites for AP-1 (Fig 4). This led us to hypothesize an indirect action of 
the ER-α involving these transcription factors. To test this, we evaluated the 
effect of EE on expression of c-JUN and c-FOS. We found that c-JUN but not c-
FOS protein level was increased in ER-α expressing HepG2 cells after 
treatment with 50 µM EE (Fig 5A-B). To explore if c-JUN up-regulation may be 
a mediator of MRP3 induction, we analyzed the effect of c-JUN over-expression
on MRP3 levels. HepG2 cells were co-transfected with c-JUN together with ER-
α cDNA or their empty vectors as controls. As shown in Fig 5C, over-
expression of c-JUN in ER-α expressing cells led to up-regulation of MRP3, 
even in the absence of incubation with EE, and to a similar extent to that
produced by EE treatment in cells transfected with ER-α only. This same Fig 
also shows that EE treatment of cells overexpressing c-JUN did not further 
increase MRP3 expression when compared with these same cells incubated
with EE vehicle. ER-α non-expressing HepG2 cells did not show any increase
in MRP3 protein levels in response to transfection with c-JUN (Fig 5D). To 
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further confirm that c-JUN modulation is unambiguously involved in MRP3 up-
regulation, we knocked down c-JUN and tested the effect of EE on MRP3 
expression. Figure 6A demonstrates a decrease of 50% in c-JUN protein level
in ER-α-transfected HepG2 cells after treatment with small interference RNA 
(siRNA), either in the presence or absence of EE in the incubation medium. As 
shown in Fig 6B, knock-down of c-JUN prevented from any MRP3 induction by 
EE. In contrast, treatment of control siRNA scrambled-transfected HepG2 cells 
with EE resulted in up-regulation of MRP3 by 230% (Fig 6B). This induction is
similar in extent to that shown above for cells not transfected with siRNA or its 
control (Fig 3A).
3.3. c-JUN interacts with ER and binds to the mrp3 promoter after EE 
stimulus.
The mrp3 proximal promoter region lacks ERE elements but contains 
AP-1 binding consensus elements (Fig 4). Our results strongly suggest that ER-
αpresence and c-JUN up-regulation are needed for EE to induce MRP3 
expression. Because both actions are needed at the same time, we further 
investigated whether EE treatment promotes ER-α/AP-1 interaction. We 
performed co-immunoprecipitation studies in ER-α-transfected HepG2 cells.
We observed that a greater fraction of ER-α co-precipitated with c-JUN in the 
EE treated cells (Fig 7A). This ER-α/c-JUN interaction was confirmed by 
reverse co-immunoprecipitation with ER-α. In this case, the amount of c-JUN
associated with ER-α was greater in EE-treated cells than in control cells (Fig
7B).
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To address whether c-JUN is recruited to the promoter region of mrp3
after EE treatment, we performed ChIP assays using two pairs of primers that 
include the two putative AP-1 binding sites identified in the mrp3 promoter 
region (Fig 4). The data show that specific anti c-JUN antibody, but not the non-
immune IgG control, successfully co-immunoprecipitated c-JUN with significant 
quantities of the mrp3 promoter (-1300/-1078 bp). Interestingly, in cells treated 
with EE, the amount of mrp3 promoter immunoprecipitated with c-JUN
increased significantly (Fig 7C), indicating that EE promotes the binding of AP-1 
to the (-1300/-1078 bp) region of the endogenous mrp3 promoter. No 
amplification product was detected with the primers ChIP 3 and ChIP 4 (-501/ -
318 bp) (data not shown).
4. DISCUSSION.
ER activated by ligand can regulate transcription through either a
classical or a non-classical mechanisms (15). The in silico analysis of the mrp3
promoter region did not show any ERE sequence but showed several potential
binding sites for AP-1. Based on this information, we proposed that EE-
induction of mrp3 transcription is mediated by ER-α acting not on ERE 
sequences but on Sp1 or AP-1 elements (non-classical pathway). Regulation of 
AP-1 activity can be achieved through changes in transcription of genes
encoding AP-1 subunits, independent of changes in its phosphorylation status
(24, 25). We found that c-JUN protein expression was increased in nuclear 
extracts from HepG2 cells transfected with ER-α and incubated with EE, and
Page 16 of 37
Ac
ce
pte
d M
an
us
cri
pt
16
that over-expression of c-JUN led to induction of MRP3 expression to the same 
extent as found under EE treatment conditions. Experiments in c-JUN knock-
down cells confirmed that this transcription factor is indeed involved in MRP3 
up-regulation by EE. Whether AP-1 non-classical pathway is the only 
mechanism mediating MRP3 induction by EE is uncertain, however, the 
experiments showing that MRP3 induction by c-JUN over-expression was not
further exacerbated by EE treatment (Fig 5C), strongly pointed to c-JUN 
induction as a key player.
Several other studies indirectly implicate AP-1 as a key mediator in 
increasing Mrp3/MRP3 expression. AP-1 transcriptional activity is increased 
300% in HepG2 cells after exposure to taurolithocholic acid (26), and could 
explain findings of Teng et al. (27) demonstrating that taurolithocholic acid 
increased MRP3 mRNA in human hepatoma HuH7 cell line. Bile duct ligation in 
mice increases AP-1 binding activity in liver (28), which could be linked to 
studies demonstrating that Mrp3 is up-regulated in liver of bile-duct ligated rats 
(29). Liver of mice treated with lipopolysaccharide showed an increase of AP-1 
binding activity detected by gel shift assays (30), whereas independent studies 
described an up-regulation of Mrp3 after similar treatment in rats (31, 32). It was 
reported that binding of c-Jun to electrophile responsive elements (EpRE)
sequences increased subsequent to 4-hydroxy-2-nonenal exposure in HepG2 
cells (33), and at the same time produces a marked up-regulation of MRP3 in 
human bronchial epithelial and Keap1 wild-type non-small-cell lung carcinoma
(NSCLC) cells (34). Appropriate experiments are needed to establish whether 
AP-1 activation and Mrp3 up-regulation are causally or casually related under 
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conditions different from that of EE treatment. MRP3/Mrp3 up-regulation was 
demonstrated to be an adaptive response to deal with liver toxicity of harmful 
endogenous metabolites, xenobiotics and drugs, either under cholestatic or 
non-cholestatic conditions (7, 35). We proposed AP-1 activation to be a 
significant participant in this adaptive response.
The mechanisms to explain the increased expression of c-JUN by EE, 
and the subsequent interaction with the promoter region of mrp3, remain poorly 
understood. It was demonstrated that human c-Jun promoter region has 
several transcription factor binding sites including AP-1 sites (36), indicating 
that c-Jun could be positively auto-regulated. Oxidative metabolites of EE, i.e., 
the 2-OH and 4-OH catechols, produce reactive oxygen species in rat liver (37), 
which in turn up-regulate AP-1 (38). It is thus possible that these same species 
contribute to AP-1 induction in our experimental conditions. Further studies are 
necessary to elucidate the mechanism of AP-1 up-regulation by EE. Our 
findings demonstrating that the over-expression of AP-1 requires the presence 
of ER-α to induce MRP3 suggest that they might need to interact with each 
other. This hypothesis was confirmed by co-immunoprecipitation assays, which 
further demonstrated that EE likely exacerbated this interaction. Moreover, 
ChIP analysis shows that from the two putative mrp3 promoters containing AP-
1 binding sites, only the distal one (-1300/-1078 bp) binds the complex c-JUN/
ER-α.
In conclusion, the present data demonstrate for the first time that EE 
induce MRP3 in HepG2 cells via ER-α through the non-classical pathway 
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mediated by AP-1. A graphical scheme summarizes the proposed mechanism 
(Fig 8).
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FIGURE LEGENDS
Figure 1: MRP3 protein expression in wild type HepG2 cells. Cells were 
incubated with 17α-ethynylestradiol (EE 1, 10 or 50 µM, 48 h) or vehicle (C). 
MRP3 was detected by Western blotting. Equal amounts of protein (15 µg) were 
loaded in all lanes. Uniformity of protein loading and transfer from gel to 
nitrocellulose membrane were controlled with Ponceau S and detection of β-
actin. Densitometric analyses represent means ± SD of 4 independent 
experiments.
Figure 2: Activity of estrogen receptor-α (ER-α) in transfected HepG2 cells.
HepG2 cells were transfected with expression plasmid vectors for ER-α or 
empty vector together with an estrogen reporter gene (4XERE-TK-Luc), and 
treated with the indicated concentrations of 17α-ethynylestradiol (EE, upper 
panel) or 17β-estradiol (E2, lower panel). Data represent mean ± SD of 4
independent experiments. a: Significantly different from control, p<0.05.
Figure 3: MRP3 protein expression in ER-α-transfected HepG2 cells.
A- MRP3 protein expression in HepG2 transfected with estrogen receptor-α 
(ER-α) vector.
B- MRP3 protein expression in HepG2 transfected with empty vector. Cells 
were incubated with 17α-ethynylestradiol (EE) or vehicle [control (C)] for 48 h. 
Equal amounts of protein (15 µg) were loaded in all lanes. Uniformity of protein 
loading and transfer from gel to nitrocellulose membrane were controlled with 
Ponceau S and detection of β-actin. Densitometric analyses represent means ± 
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SD of 4 independent experiments. a: significantly different from C, p<0.05. b: 
significantly different from 17α-ethynylestradiol (EE) 1 µM, p<0.05.
C- MRP3 mRNA expression in HepG2 cells transfected with ER-α or empty 
vector. Cells were incubated with EE (50 µM) or vehicle (C) for 48 h and mRNA 
levels were detected by real time PCR. Data are presented as a percent of 
control (100%) and were expressed as means ± SD of 4-6 independent 
experiments. 18S rRNA was used as an internal control. a: significantly different 
from C, p<0.05
Figure 4: MRP3 proximal promoter region analysis. Consensus elements for
AP-1 nuclear factors identified by TF-Search database are underlined. Numbers 
represent the positions of nucleotides in relationship to the transcription 
initiation site +1 indicated by arrows. ChIP 1, ChIP 2, ChIP 3 and ChIP 4 
represents the primers utilized in ChIP assay.
Figure 5: Involvement of c-JUN in MRP3 induction.
A- c-JUN, and B- c-FOS, protein expression in nuclear extracts from HepG2 
cells transfected with estrogen receptor-α (ER-α) and incubated with EE (50 
µM) or vehicle (C).
C- HepG2 cells transfected with ER-α vector (ERα (+)), and D- HepG2 cells 
transfected with empty vector (ERα (-)), were transfected with c-JUN (c-JUN 
(+)) or empty vector (c-JUN (-)), and incubated with EE (50 µM) or vehicle (C). 
MRP3 protein expression was then assessed by Western blotting in cell lysates.
Equal amounts of protein (5 µg for nuclear extracts and 15 µg for total lysates) 
were loaded in all lanes. Uniformity of protein loading and transfer from gel to 
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nitrocellulose membrane were controlled with Ponceau S and detection of 
histone or β-actin. Densitometric analyses represent means ± SD of 4 
independent experiments. a: significantly different from c-JUN(-) C, p<0.05.
Figure 6: MRP3 and c-JUN protein expression in c-JUN knock down HepG2 
cells.
A- c-JUN protein expression in nuclear extracts from HepG2 cells transfected 
with ER-α and c-JUN siRNA (c-JUN-) or siRNA scramble (c-JUN+).
B- MRP3 protein expression in cell lysates from HepG2 cells transfected with 
ER-α and c-JUN siRNA (c-JUN-) or siRNA scramble (c-JUN+).
Cells were incubated with 17α-ethynylestradiol (EE, 50 µM for 48 h) or vehicle 
(control (C)).
Equal amounts of protein (5 µg for nuclear extracts and 15 µg for total lysate) 
were loaded in all lanes. Uniformity of protein loading and transfer from gel to 
nitrocellulose membrane were controlled with Ponceau S and detection of 
histone or β-actin. Densitometric analyses represent means ± SD of 4 
independent experiments. a: significantly different from c-JUN (+) and c-JUN (-) 
EE, p<0.05. b: significantly different from c-JUN (+) C, c-JUN (-) C and c-JUN (-
) EE, p<0.05.
Figure 7: Interaction of ER-α with c-JUN and recruitment of c-JUN to MRP3 
promoter. ER-α-transfected HepG2 cells were treated with EE (50 µM, 48 h) or 
vehicle (control (C)). Co-immunoprecipitation assays were performed by 
treating cell lysates with either c-JUN antibody or normal rabbit IgG followed by 
Western blot detection of ER-α (A) or by treating cell lysates with either ER-α 
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antibody or normal rabbit IgG followed by Western blot detection of c-JUN (B). 
The inputs represent 2% of total proteins in the cell lysates. (C) ChIP assay for 
detection of c-JUN association to MRP3 promoter. An unrelated antibody, anti 
IgG, was used as control. Similar results were obtained in a separated 
experiment.
IP: immunoprecipitation.
Figure 8: ER-α and c-JUN mediation of human MRP3 up-regulation by 17-
α-ethynylestradiol (EE). The graphical scheme represents a sequence of 
events starting with EE treatment of the HepG2 cells and leading ultimately to 
induction of human MRP3 protein expression. As a first step of this sequence, 
EE induces up-regulation of a major component of AP-1, c-JUN. Secondly, in 
order to induce the expression of MRP3, c-JUN interacts with ER-α and the 
resulting complex is recruited to a specific promoter region of the human mrp3
gene. On this regard, two putative regions were found to be potential targets for 
the complex to bind to, but only one of them showed to be involved in the 
current experimental conditions.
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FOOTNOTES.
These experiments were partially presented as a poster in the 47th
International Liver Congress 2012 in Barcelona, Spain. The presentation was 
selected as TOP 10% by the EASL committee.
Abbreviations: MRP3, multidrug resistance-associated protein 3; EE, 17α-
ethynylestradiol; ER, estrogen receptor; AP-1, activating protein-1; DMEM, 
Dulbecco´s Modified Eagle´s Medium; FBS, fetal bovine serum; ERE, estrogen 
response elements.
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